132 related articles for article (PubMed ID: 31324563)
1. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs.
Draganov AB; Yang X; Anifowose A; De La Cruz LKC; Dai C; Ni N; Chen W; De Los Santos Z; Gu L; Zhou M; Wang B
Bioorg Med Chem; 2019 Sep; 27(17):3860-3865. PubMed ID: 31324563
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core.
Tripathi R; Anifowose A; Lu W; Yang X; Wang B
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2370-2381. PubMed ID: 36043494
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs.
Anifowose A; Yuan Z; Yang X; Pan Z; Zheng Y; Zhang Z; Wang B
Bioorg Med Chem Lett; 2020 Jan; 30(2):126786. PubMed ID: 31753697
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
6. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
[TBL] [Abstract][Full Text] [Related]
8. Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype.
Volodina YL; Tikhomirov AS; Dezhenkova LG; Ramonova AA; Kononova AV; Andreeva DV; Kaluzhny DN; Schols D; Moisenovich MM; Shchekotikhin AE; Shtil AA
Eur J Med Chem; 2021 Oct; 221():113521. PubMed ID: 34082225
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
[TBL] [Abstract][Full Text] [Related]
11. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
[TBL] [Abstract][Full Text] [Related]
12. Design and Syntheses of Novel Fluoroporphyrin-Anthraquinone Complexes as Antitumor Agents.
Yang GL; Zhao SF; Chen NY; Li S
Chem Pharm Bull (Tokyo); 2016; 64(9):1310-4. PubMed ID: 27581635
[TBL] [Abstract][Full Text] [Related]
13. Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
Grigoreva TA; Novikova DS; Petukhov AV; Gureev MA; Garabadzhiu AV; Melino G; Barlev NA; Tribulovich VG
Bioorg Med Chem Lett; 2017 Dec; 27(23):5197-5202. PubMed ID: 29089230
[TBL] [Abstract][Full Text] [Related]
14. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
15. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
16. Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties.
Tikhomirov AS; Litvinova VA; Andreeva DV; Tsvetkov VB; Dezhenkova LG; Volodina YL; Kaluzhny DN; Treshalin ID; Schols D; Ramonova AA; Moisenovich MM; Shtil AA; Shchekotikhin AE
Eur J Med Chem; 2020 Aug; 199():112294. PubMed ID: 32428792
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyl Group Difference between Anthraquinone Derivatives Regulate Different Cell Death Pathways via Nucleo-Cytoplasmic Shuttling of p53.
Kamil M; Haque E; Mir SS; Irfan S; Hasan A; Sheikh S; Alam S; Ansari KM; Nazir A
Anticancer Agents Med Chem; 2019; 19(2):184-193. PubMed ID: 30370860
[TBL] [Abstract][Full Text] [Related]
20. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
